Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RELUGOLIX for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 65 adverse event reports in the FDA FAERS database where RELUGOLIX was used for Neoplasm malignant.

Most Reported Side Effects for RELUGOLIX

Side Effect Reports % Deaths Hosp.
Hot flush 6,845 33.1% 22 313
Fatigue 5,203 25.2% 44 297
Therapy interrupted 3,251 15.7% 20 99
Incorrect dose administered 1,917 9.3% 39 204
Asthenia 1,718 8.3% 25 182
Arthralgia 1,385 6.7% 6 93
Diarrhoea 1,383 6.7% 11 107
Product dose omission issue 1,189 5.8% 16 155
Dizziness 1,146 5.6% 10 105
Constipation 902 4.4% 9 84
Death 832 4.0% 832 74
Weight increased 805 3.9% 3 42
Insomnia 764 3.7% 3 60
Pain 750 3.6% 13 101
Myalgia 721 3.5% 5 44

Other Indications for RELUGOLIX

Prostate cancer (18,752) Product used for unknown indication (1,417) Uterine leiomyoma (115) Prostate cancer metastatic (42) Heavy menstrual bleeding (32) Endometriosis (23) Prostatic specific antigen increased (15) Adenomyosis (14) Hormone-refractory prostate cancer (13) Anaemia (10)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

RELUGOLIX Full Profile All Neoplasm malignant Drugs RELUGOLIX Demographics RELUGOLIX Timeline